Noseworthy, JH, Lucchinetti, C, Rodriguez, M, Weinshenker, BG.
Multiple sclerosis. NEJM. 2000;343:938–52.
Mikol, DD, Barkhof, F, Chang, P, Coyle, PK, Jeffery, DR, Schwid, SR, et al.
Comparison of subcutaneous interfereon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (REGARD study): a mulicentre, randomised, parallel, openlabel trial. Lancet Neurol. 2008;7:903–14.
Goodin, DS, Cohen, BA, O’Connor, P.
Assessment: the use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2008;71:766–73.
O’Connor, P, Devonshire, V., Canadian Network of MS Clinics. The use of disease-modifying agents in multiple sclerosis - by the Canadian network of MS clinics. Can J Neurol Sci. 2008;35: 127–32.
Beck, CA, Metz, LM, Svenson, LW, Patten, SB.
Regional variation of multiple sclerosis prevalence in Canada. Mult Scler.
Noonan, CW, Kathman, SJ, White, MC.
Prevalence estimates for MS in the United Sates and evidence of an increasing trend for women. Neurology. 2002;58:136–8.
Berg, J, Lindgren, P, Fredrikson, S, Kobelt, G.
Costs and quality of life of multiple sclerosis in Sweden. Eur J Health Econ.
Kobelt, G, Berg, J, Atherly, D, Hadjimichael, O.
Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States. Neurology. 2006;66:1696–702.
Imshealthcanada.com [homepage on the Internet]. Toronto: IMS Health Incorporated; c2009 [cited 2009 Oct 12]. Available from: http://www.imshealthcanada.com/
Jacobs, LD, Beck, RW, Simon, JH, Kinkel, RP, Brownscheidle, CM, Murray, TJ, et al.
Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. NEJM. 2000;343(13):898–904.
Kinkel, RP, Kollman, C, O’Connor, P, Murray, TJ, Simon, J, Arnold, D, et al.
IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology. 2006;66(5): 678–84.
Goodin, DS, Frohman, EM, Garmany, GP, Halper, J, Likosky, WH, Lublin, FD, et al.
Disease modifying therapies in multiple sclerosis. Report of the Therapy and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. February 2002.
Canadian Institute of Health Information. National survey of selected medical imaging equipment; 2003-2007.
The European Study Group on interferon beta-1b in secondary progressive MS. Placebo controlled multicentre randomized trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet. 1998;352(9139):1491–7.
Panitch, H, Miller, A, Paty, D, Weinshenker, B.
North American Study Group on Interferon beta-1b in Secondary Progressive MS. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology. 2004;63(10):1788–95.
Hauser, SL, Johnston, SC.
Scripts for science: a new wrinkle on academic ties with industry. Ann Neurol.
Warren, SA, Svenson, LW, Warren, KG.
Contribution of incidence to increasing prevalence of MS in Alberta, Canada. Mult Scler. 2008;14:872–9.
Jackevicius, CA, Tu, JV, Ross, JS, Ko, DT, Krumholz, HM.
Use of ezetimibe in the United States and Canada. NEJM.
Tu, JV, Pashos, CL, Naylor, CD, Chen, E, Normand, S-L, Newhouse, JP, et al.
Use of cardiac procedures and outcomes in elderly patients with myocardial infarction in the United States and Canada. NEJM. 1997;336(21):1500–5.